Cubist Pharmaceuticals picked up FDA approval for its latest antibiotic contender, a potential blockbuster whose promise helped bring Merck to the table with a $9.5 billion buyout offer.

…read more

Source: Cubist scores another FDA nod on the eve of its $9.5B Merck merger